Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 8, 2012, Pages 1319-1329

  Hyde, Zoë ^a,b   Flicker, Leon ^a,b   McCaul, Kieran A ^a,b   Almeida, Osvaldo P ^a,c,d   Hankey, Graeme J ^b,d   Chubb, S A Paul ^b,e   Yeap, Bu B ^b,e  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e FREMANTLE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGED; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; FOLLOW UP; HORMONE BLOOD LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TESTOSTERONE BLOOD LEVEL;

EID: 84864796325     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0129     Document Type: Article

References (53)

1. Australian Institute of Health and Welfare, Australasian Association of Cancer Registries. Cancer in Australia: in brief 2010. Canberra: AIHW; 2010.
2. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-20. (Pubitemid 35428875)
3. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol 1997;15:21-6. (Pubitemid 127769831)
4. Cunningham GR, Toma SM. Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011;96:38-52.
5. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17:R305-15.
6. Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol Biomarkers Prev 2005;14:2257-60. (Pubitemid 41603276)
7. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26. (Pubitemid 26274606)
8. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170-83. (Pubitemid 351480553)
9. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847-53. (Pubitemid 30106616)
10. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? Prostate Cancer Prostatic Dis 2006;9:14-8. (Pubitemid 43378862)
11. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33. (Pubitemid 34761611)
12. Chlebowski RT, Schwartz AG, Wakelee H, Anderson GL, Stefanick ML, Manson JE, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009;374:1243-51.
13. Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, et al. Low free testosterone predicts mortality from cardiovascular disease, but not other causes. The Health in Men Study. J Clin Endocrinol Metab 2012;97:179-89.
14. Maasberg M, Rotsch M, Jaques G, Enderle-Schmidt U, Weehle R, Havemann K. Androgen receptors, androgen-dependent proliferation, and 5 alpha-reductase activity of small-cell lung cancer cell lines. Int J Cancer 1989;43:685-91. (Pubitemid 19110106)
15. English KM, Pugh PJ, Parry H, Scutt NE, Channer KS, Jones TH. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci (Lond) 2001;100:661-5. (Pubitemid 32523320)
16. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort profile: the Health in Men Study (HIMS). Int J Epidemiol 2009;38:48-52.
17. Yeap BB, Almeida OP, Hyde Z, Norman PE, Chubb SAP, Jamrozik K, et al. Inmenolder than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol 2007;156:585-94. (Pubitemid 46796526)
18. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72. (Pubitemid 30645223)
19. Sartorius G, Ly LP, Sikaris K, McLachlan R, Handelsman DJ. Predictive accuracy and sources of variability in calculated free testosterone estimates. Ann Clin Biochem 2009;46:137-43.
20. Hackbarth JS, Hoyne JB, Grebe SK, Singh RJ. Accuracy of calculated free testosterone differs between equations and depends on gender and SHBG concentration. Steroids 2011;76:48-55.
21. Holman CD, Bass AJ, Rouse IL, Hobbs MS. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999;23:453-9. (Pubitemid 29479210)
22. Threlfall TJ, Thompson JR. Cancer incidence and mortality in Western Australia, 2008. Perth: Department of Health, Western Australia; 2010.
23. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
24. Calistro Alvarado L. Population differences in the testosterone levels of young men are associated with prostate cancer disparities in older men. Am J Hum Biol 2010;22:449-55.
25. Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, et al. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:86-91.
26. Khosla S. Editorial: sex hormone binding globulin: inhibitor or facilitator (or both) of sex steroid action? J Clin Endocrinol Metab 2006;91:4764-6. (Pubitemid 44917303)
27. Noble RL. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res 1977;37:1929-33. (Pubitemid 8095214)
28. Shirai T, Sano M, Imaida K, Takahashi S, Mori T, Ito N. Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2′-dimethyl-4- aminobiphenyl and development of androgen-independent carcinomas after castration. Cancer Lett 1994;83:111-6.
29. Morgentaler A, Bruning CO 3rd, DeWolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996;276:1904-6. (Pubitemid 26419188)
30. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001;47:52-8. (Pubitemid 32246752)
31. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449-53. (Pubitemid 29476696)
32. Meikle AW, Smith JA, Stringham JD. Production, clearance, and metabolism of testosterone in men with prostatic cancer. Prostate 1987;10:25-31. (Pubitemid 17037647)
33. Prehn RT. On the prevention and therapy of prostate cancer by androgen administration. Cancer Res 1999;59:4161-4. (Pubitemid 29418717)
34. Algarte-Genin M, Cussenot O, Costa P. Prevention of prostate cancer by androgens: experimental paradox or clinical reality. Eur Urol 2004;46:285-94; discussion 94-5.
35. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
36. Cohen YC, Liu KS, Heyden NL, Carides AD, Anderson KM, Daifotis AG, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74. (Pubitemid 351767189)
37. Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1375-83. (Pubitemid 351767184)
38. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-64. (Pubitemid 36331852)
39. Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994;8:439-43.
40. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation Into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701. (Pubitemid 350291241)
41. Izbicki JR, Hamilton SR, Wambach G, Harnisch E, Wilker DK, Dornschneider G, et al. Effects of androgen manipulations on chemically induced colonic tumours and on macroscopically normal colonic mucosa in male Sprague-Dawley rats. Br J Cancer 1990;61:235-40. (Pubitemid 20058282)
42. Guan RJ, Ford HL, Fu Y, Li Y, Shaw LM, Pardee AB. Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer. Cancer Res 2000;60:749-55. (Pubitemid 30094577)
43. Nielsen HC. Testosterone regulation of sex differences in fetal lung development. Proc Soc Exp Biol Med 1992;199:446-52.
44. Patrone C, Cassel TN, Pettersson K, Piao YS, Cheng G, Ciana P, et al. Regulation of postnatal lung development and homeostasis by estrogen receptor beta. Mol Cell Biol 2003;23:8542-52. (Pubitemid 37441291)
45. Mikkonen L, Pihlajamaa P, Sahu B, Zhang FP, Janne OA. Androgen receptor and androgen-dependent gene expression in lung. Mol Cell Endocrinol 2010;317:14-24.
46. Sorenson GD, Pettengill OS, Brinck-Johnsen T, Cate CC, Maurer LH. Hormone production by cultures of small-cell carcinoma of the lung. Cancer 1981;47:1289-96. (Pubitemid 11090492)
47. Ramaeker D, Brannian J, Egland K, McCaul K, Hansen K. When is elevated testosterone not testosterone? When it is an immunoassay interfering antibody. Fertil Steril 2008;90:886-8.
48. Slevin TJ, Donnelly N, Clarkson JP, English DR, Ward JE. Prostate cancer testing: behaviour, motivation and attitudes among Western Australian men. Med J Aust 1999;171:185-8. (Pubitemid 29392790)
49. O'Brien BA, Brown AL, Shannon T, Cohen RJ. Prostate biopsy in Western Australia 1998-2004. Prostate Cancer Prostatic Dis 2010;13:263-9.
50. Vermeulen A, Verdonck G. Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 1992;74:939-42.
51. Vickers AJ. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents. BMC Med Res Methodol 2012;12:21.
52. Greenland S. Avoiding power loss associated with categorization and ordinal scores in dose-response and trend analysis. Epidemiology 1995;6:450-4.
53. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-59.